RD06-05 clinical trials
How each study uses RD06-05 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the RD06-05 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Nanjing Bioheng Biotech Co., Ltd. (3) · The Children's Hospital of Zhejiang University School of Medicine (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test RD06-05.
- Jan 2027Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune DiseasesEarly Phase 1 · Nanjing Bioheng Biotech Co., Ltd.
- Jul 2027A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.Early Phase 1 · Nanjing Bioheng Biotech Co., Ltd.
Studies
Open first, then newest update. How each study uses RD06-05 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.RecruitingEarly Phase 1Nanjing Bioheng Biotech Co., Ltd.NCT07203404Written as RD06-05 CART Cell Injection
- CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune DiseasesNot yet recruitingEarly Phase 1Nanjing Bioheng Biotech Co., Ltd.NCT07596680Written as RD06-05 CAR-T Cell Injection
- RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune DiseasesNot yet recruitingEarly Phase 1The Children's Hospital of Zhejiang University School of MedicineNCT07674147Written as RD06-05 CART Cell Infusion
- Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune DiseasesRecruitingEarly Phase 1Nanjing Bioheng Biotech Co., Ltd.NCT06775912Written as RD06-05 CART Cell Injection
- Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel DiseaseNot yet recruitingEarly Phase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07309744Written as RD06-05 CART Cell Infusion